Fundraising Fox
/Companies
Sign in

Oricell Therapeutics

Shanghai, CN · Founded 2015 · 24 employees on LinkedIn · 4 known investors

Find your way into Oricell Therapeutics

Sign up to see every warm intro you have to Oricell Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Oricell Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Oricell Therapeutics (原启生物) is a clinical-stage biopharmaceutical company developing cell therapies, including CAR-T products targeting GPRC5D for relapsed/refractory multiple myeloma and GPC3 for advanced liver cancer. Based in Shanghai, it builds proprietary antibody and CAR platforms (OriAb, OriCAR) to create cancer immunotherapies for unmet oncology needs such as liver, gastric, pancreatic, biliary, and ovarian cancers.

BiotechDeep TechHealthtech

Founders & leadership

Oricell Therapeutics was founded in 2015 by Helen Yang.

HYHelen Yang
Helen YangCo-founder/Chairwoman/CEOHelen Yang has nearly 30 years of experience in capital operations and management at entrepreneurial and public companies, including board secretary and president roles at two public firms. She co-founded Canature Health and oversaw its IPO on ChiNext, and has served as Chairman and CEO of Oricell Therapeutics since 2015, where she established the company's antibody and CAR-T cell therapy platforms.
IHIris Huang
Iris HuangShe joined Oricell Therapeutics as Chief of Staff in 2023 after an investment banking career that included roles as Vice President and Executive Director at J.P. Morgan. She began at Bank of America Merrill Lynch in 2015, advancing from analyst to Vice President.

Investors · 4

Vivo Capital✓ confirmed by Oricell TherapeuticsPalo Alto · $10M – $50M

How we know: Vivo Capital's portfolio page · the company's own site · funding news · Not right? Tell us

Quan Capitallisted by Quan CapitalShanghai
RTW Investments L.P.reportedNew York

How we know: a partner's Signal profile · Not right? Tell us

Funding

SEC filings, press & company announcements

$110M disclosed across 1 of 2 rounds · 2026

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Oricell Therapeutics Closes $110M Pre-IPO Financingfinsmes.com · Apr 2026Oricell Therapeutics Announces US$70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapiesprnewswire.com · Jan 2026

Frequently asked questions

What does Oricell Therapeutics do?
Oricell Therapeutics (原启生物) is a clinical-stage biopharmaceutical company developing cell therapies, including CAR-T products targeting GPRC5D for relapsed/refractory multiple myeloma and GPC3 for advanced liver cancer. Based in Shanghai, it builds proprietary antibody and CAR platforms (OriAb, OriCAR) to create cancer immunotherapies for unmet oncology needs such as liver, gastric, pancreatic, biliary, and ovarian cancers.
Who founded Oricell Therapeutics?
Oricell Therapeutics was founded by Helen Yang in 2015.
Who are Oricell Therapeutics's investors?
Oricell Therapeutics's investors include Qiming Venture Partners, Vivo Capital, Quan Capital, RTW Investments L.P..
How much funding has Oricell Therapeutics raised?
Oricell Therapeutics has disclosed $110M raised across 1 of its 2 known rounds.
Where is Oricell Therapeutics headquartered?
Oricell Therapeutics is headquartered in Shanghai, CN.